BSX Boston Scientific Corporation

Price (delayed)

$39.31

Market cap

$55.01B

P/E Ratio

12.76

Dividend/share

N/A

EPS

$3.08

Enterprise value

$64.97B

Sector: Healthcare
Industry: Medical Devices
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Highlights

The P/E is 57% below the last 4 quarters average of 29.5
The equity has grown by 50% YoY
Boston Scientific's net income has surged by 139% YoY but it has decreased by 9% QoQ
The EPS has soared by 137% YoY but it has decreased by 9% from the previous quarter
Boston Scientific's debt has increased by 12% YoY and by 3.3% QoQ

Key stats

What are the main financial stats of BSX
Market
Shares outstanding
1.4B
Market cap
$55.01B
Enterprise value
$64.97B
Valuations
Price to earnings (P/E)
12.76
Price to book (P/B)
3.98
Price to sales (P/S)
5.09
EV/EBIT
92.29
EV/EBITDA
37.89
EV/Sales
6.02
Earnings
Revenue
$10.79B
EBIT
$704M
EBITDA
$1.72B
Free cash flow
$919M
Per share
EPS
$3.08
Free cash flow per share
$0.66
Book value per share
$9.89
Revenue per share
$7.72
TBVPS
$9.03
Balance sheet
Total assets
$30.11B
Total liabilities
$16.31B
Debt
$10.34B
Equity
$13.8B
Working capital
$847M
Liquidity
Debt to equity
0.75
Current ratio
1.21
Quick ratio
0.49
Net debt/EBITDA
5.81
Margins
EBITDA margin
15.9%
Gross margin
70.4%
Net margin
39.7%
Operating margin
10.4%
Efficiency
Return on assets
15.3%
Return on equity
36.6%
Return on invested capital
4.3%
Return on capital employed
2.7%
Return on sales
6.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BSX stock price

How has the Boston Scientific stock price performed over time

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$10.79B
Gross profit
$7.59B
Operating income
$1.12B
Net income
$4.29B
Gross margin
70.4%
Net margin
39.7%
Boston Scientific's net income has surged by 139% YoY but it has decreased by 9% QoQ
Boston Scientific's net margin has surged by 119% YoY but it has decreased by 9% QoQ
BSX's operating margin is down by 37% year-on-year and by 26% since the previous quarter
Boston Scientific's operating income has decreased by 32% YoY and by 26% from the previous quarter

Valuation

What is Boston Scientific stock price valuation
P/E
12.76
P/B
3.98
P/S
5.09
EV/EBIT
92.29
EV/EBITDA
37.89
EV/Sales
6.02
The EPS has soared by 137% YoY but it has decreased by 9% from the previous quarter
The P/E is 57% below the last 4 quarters average of 29.5
The equity has grown by 50% YoY
The stock's price to book (P/B) is 20% less than its 5-year quarterly average of 5.0 and 20% less than its last 4 quarters average of 5.0
BSX's P/S is 16% above its 5-year quarterly average of 4.4 but 6% below its last 4 quarters average of 5.4
The revenue has increased by 9% YoY

Efficiency

How efficient is Boston Scientific business performance
The return on assets has surged by 80% year-on-year but it has declined by 14% since the previous quarter
BSX's ROIC has plunged by 78% YoY and by 44% from the previous quarter
The return on equity has surged by 74% year-on-year but it has declined by 18% since the previous quarter
The ROS has plunged by 65% YoY and by 40% from the previous quarter

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 85% more than its total liabilities
BSX's quick ratio is up by 26% year-on-year and by 17% since the previous quarter
BSX's current ratio is up by 25% since the previous quarter but it is down by 13% year-on-year
Boston Scientific's debt is 25% lower than its equity
Boston Scientific's debt to equity has decreased by 25% YoY but it has increased by 4.2% from the previous quarter
Boston Scientific's debt has increased by 12% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.